Aurora Cannabis (ACB) Income towards Parent Company (2017 - 2026)
Aurora Cannabis (ACB) posted quarterly Income towards Parent Company of $4.4 million for Q1 2026, up 174.14% year-on-year from $1.6 million in Q1 2025, and down 98.85% on a QoQ basis from $384.6 million in Q4 2025.
Aurora Cannabis (ACB) Income towards Parent Company (2017 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Income towards Parent Company for 10 consecutive years, with $4.4 million the latest figure, recorded in Q1 2026.
- Quarterly Income towards Parent Company rose 174.14% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$548.6 million (up 48.66% YoY) and the FY2026 annual result came in at -$42.4 million, down 110.4% from the prior year.
- Income towards Parent Company slipped to $4.4 million in Q1 2026 per ACB's latest filing, from $384.6 million in the prior quarter.
- Over the last five years, Income towards Parent Company for ACB reached as high as $860.2 million in Q1 2022 and fell as low as -$545.4 million in Q4 2022.
- A 5-year average of $186.1 million and a median of $375.8 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2022 — Income towards Parent Company sank 4195.43% — and 2026, when it surged 174.14%.
- Year by year, Income towards Parent Company stood at -$545.4 million in 2022, then soared by 169.56% to $379.4 million in 2023, then climbed by 8.11% to $410.1 million in 2024, then decreased by 6.22% to $384.6 million in 2025, then slumped by 98.85% to $4.4 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered $4.4 million, $384.6 million, and $386.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Aurora Cannabis | 155.40 Mn | 70.15 Mn | 21.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.43 Mn |
| Dec 31, 2025 | 384.62 Mn |
| Sep 30, 2025 | 386.51 Mn |
| Jun 30, 2025 | 398.33 Mn |
| Mar 31, 2025 | -5.97 Mn |
| Dec 31, 2024 | 410.12 Mn |
| Sep 30, 2024 | 398.17 Mn |
| Jun 30, 2024 | 410.62 Mn |
| Mar 31, 2024 | -1.65 Mn |
| Dec 31, 2023 | 379.35 Mn |
| Sep 30, 2023 | 375.79 Mn |
| Jun 30, 2023 | 354.16 Mn |
| Mar 31, 2023 | 359.55 Mn |
| Dec 31, 2022 | -545.38 Mn |
| Sep 30, 2022 | -515.60 Mn |
| Jun 30, 2022 | -488.98 Mn |
| Mar 31, 2022 | 860.20 Mn |
| Dec 31, 2021 | 1.55 Bn |
| Sep 30, 2021 | -12.00 Mn |
| Jun 30, 2021 | -87.26 Mn |